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Materials and Methods 
 
Synthesizing the synthetic macromer. 
The acetyl-NQEQVSPLTLLKKGC (Thermo Fisher Scientific, Waltham, USA) peptide derived 
from α2-antiplasmin was conjugated to polyethylene glycol maleimide (PEG-mal) (40 kDa, 8-
armed) (Creative PEGWorks, Winston Salem, USA).  To reduce disulfide coupling of the 
peptides, the peptide solution (20 mg/mL, 12.5 mM) was run through an immobilized Tris-(2-
carboxyethyl)phosphine (TCEP) disulfide reducing gel (Thermo Fisher Scientific).  For the 
conjugation reaction, the peptides were reacted with PEG-mal (50 mg/mL, 1.25 mM) in Tris-
EDTA buffer (150 mM NaCl, 50 mM Tris-Base, 10 mM EDTA, pH 8) overnight at 4⁰C, stirring 
continuously.  To quench any remaining unreacted maleimide, mercaptoethanol (180 µM) was 
added to the mixture.  This mixture was then dialyzed against Tris-EDTA buffer for 1 day, and 
then against water for 2 days.  To confirm the conjugation of PEG-mal and peptides, Ellman’s 
reagent (5,5'-dithiobis(2-nitrobenzoate) (DTNB), Sigma), a sensitive reagent for measuring free 
sulfhydryl content, was used to detect free thiols on the peptide.  Free thiols on the peptide 
significantly decreased and were eliminated following conjugation with PEG-mal and 
subsequent dialysis.  The dialyzed solution was purified further using a desalting column (Zeba 
Spin Desalting Columns, 7k MWCO, Thermo Fisher Scientific) and then the purified conjugates 
were concentrated by a Centri-prep filter (Amicon®Ultra 10K, Millipore).  The final conjugates 
were lyophilized and stored at -20⁰C until use.  The molecular weight of the modified PEG-mal 
was measured by Matrix-Assisted Laser Desorption Ionization-Tandem Time of Flight (MALDI-
TOF) to confirm conjugation with peptides, comparing it to the molecular weight of unmodified 
PEG-mal (see Supplementary Fig. S4).  The size of the mass shift indicated that 
approximately all the maleimide groups conjugated to peptides. 
 
Testing the rate of fibrin clot formation in response to known modulators. 
Frozen normal human plasma was thawed at 37⁰C and recalcified.  The recalcification solution 
(90 mM NaCl and 40 mM CaCl2) was added to the plasma in a 1:3 ratio.  Each modulator was 
separately added to this mixture (concentrations stated in Supplementary Table S2) and 
samples were maintained at 37⁰C. 
 
Testing the formation time of the BNC-material in response to modulators. 
A reaction mix was prepared in buffer (10 mM HEPES, 7 mM sodium citrate, pH 7.4) 
containing the synthetic macromers (49 mg/mL), fibrinogen-deficient plasma (13.3% v/v) 
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(Affinity Biologicals, Ancaster, Canada), purified FXIII (93 μg/mL) (Haematologic Technologies 
Inc., Vermont, USA), spermidine (1.8 mM) (Sigma-Aldrich, St. Louis, USA), dithiothreitol (DTT; 
0.66 mM) (Sigma-Aldrich, St. Louis, USA), and CaCl2 (29 mM) (Acros Organics, New Jersey, 
USA).  The stimuli being evaluated were added to this mixture at the test concentrations stated 
in Supplementary Table S2 and the reaction was maintained at 37⁰C.  Fibrinogen-deficient 
plasma partially depleted for other coagulation factors was used in Fig. 2d, e, g and 3.  
Specific enzyme activities for this plasma are listed in Supplementary Table S1. A higher 
concentration of fibrinogen-deficient plasma (26.6% v/v) and lower concentration of 
supplemented purified FXIII (46.5 μg/mL) was used in Fig. 2f.  The gelation time was 
consistent over a wide range of concentrations for most stimuli (Supplementary Table S2).  
 
Gelling the synthetic macromer using purified FXIIIa, without plasma. 
The same protocol for forming the BNC-material was used with minor modifications. The 
reaction mixture was made in the same citrated buffer containing the synthetic macromers (87 
mg/mL), human FXIIIa (0.31 mg/mL, unless otherwise stated) (Haematologic Technologies 
Inc., Vermont, USA), spermidine (2.4 mM), DTT (0.90 mM), and CaCl2 (9.4 mM).  No blood 
plasma was added. In the experiments in which different stimuli were tested, stimuli were 
added to this mixture at concentrations specified in Supplementary Table S2.  The reaction 
mixture was maintained at 37⁰C. 
 
Assessing the mechanical properties of the synthetic polymer and fibrin clots. 
The mechanical properties of the BNC-material and fibrin clots were measured during the 
course of their formation by thromboelastography (TEG) (TEG® 5000 Thrombelastograph® 
Hemostasis System, Haemoscope Corporation, IL) (see Fig. 1 and Supplementary Fig. S6)1.  
TEG measures properties such as the reaction rate, mechanical strength, and stability of gel or 
clot by measuring rotational movement of a pin suspended in a gel mixture or plasma.  
Reaction time (R) indicates the time that gelation begins.  Amplitude (A) is a function of clot 
strength or elasticity.  Maximum amplitude (MA) represents the maximum strength of the gel.  
The amplitude can be used to determine the shear elastic modulus (G) of gel or fibrin clot 
during their formation.  The reaction mixture (300 µL) of the BNC-material or normal plasma 
was prepared as previously described and the reaction was initiated by recalcification and the 
addition of silica (Kontact reagent) to activate the coagulation network.  The effects of  an 
inhibitor of FXIIIa (10 mM 1,3,4,5-Tetramethyl-2-[(2-oxopropyl)thio]imidazolium chloride 
(T101), ZEDIRA GmbH, Germany) or a cocktail of protease inhibitors (2 mM 4-(2-
aminoethyl)benzenesulfonyl fluoride, 0.3 μM aprotinin, 130 μM bestatin, 1 mM EDTA, 14 μM 
E-64, 1 μM Leupeptin, Sigma-Aldrich) were evaluated.  The samples were analyzed at 37°C 
for 3 hr.  
The compressive elastic moduli of the BNC-material gels were measured by a controlled force 
compression test (DMAQ800, TA Instruments, DE).  The same protocol for forming the BNC-
material was used as described above, with individual reaction volumes of 5.79 μL. The BNC-
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material reaction mixtures were incubated overnight at 37°C to allow them to completely gel. 
Each gel was removed from its microchamber and placed in a submersion-compression clamp. 
Its diameter was measured using a caliper to determine the surface area of the sample.  
Preload force of 0.01 N was applied to the gel to ensure good contact with the compression 
clamp. The instrument measured initial sample thickness, ramped the compression force at 
0.01 N/min and measured the sample’s stress and strain. The compressive elastic modulus 
was calculated by taking the absolute value of the slope of the stress-strain curve at its initial 
linear portion where elastic deformation was observed (Supplementary Fig. S3).  
 
Assessing the gelation of the BNC-material and normal plasma clots. 
The BNC-material or normal plasma clots were formed in polypropylene tubes.  The gelation 
time was determined to be the time it took for the reaction mixture to reach a viscosity at which 
it could no longer be pipetted (see photos in Fig. 1b).  For measuring the gelation time of many 
samples simultaneously, a microscope assay was employed. Here, fluorescent beads 
(Fluoresbrite Plain YG 1.0 Micron Microsphere, Polysciences Inc., Warrington, USA) were 
suspended in the reaction mixture (6 x 108 particles/mL) and then transferred into individual 
microchambers.  These microchambers were constructed by sandwiching an adhesive silicone 
isolator (4.5 mm diameter x 0.5 mm depth; Grace Bio-Labs, Bend, USA) between two plastic 
coverslips (HybriSlip, Grace Bio-Labs, Bend, USA) (Supplementary Fig. S7).  Brownian 
motion of the green fluorescent beads within the reaction mixture was monitored via time-
course imaging using a Leica DMI6000B fluorescence microscope.  Gelation was considered 
to be complete when the fluorescent beads stopped moving. 
 
Imaging the BNC-material and fibrin clots by electron microscopy. 
Samples for conventional SEM were prepared as described previously2.  The gels were fixed 
with formalin and then dehydrated with ethanol.  These gels were carbon-coated and then 
imaged with a Hitachi S-4700 field Emission Scanning Electron Microscope.  SEM imaging 
was replicated three times.  Cryo-EM was done following previously published methods with 
slight modification3.  The gels were flash-frozen in liquid nitrogen and excess water from the 
samples was sublimed in a higher temperature vacuum chamber. The samples were then 
carbon-coated prior to imaging. 
 
Generating lipid vesicles. 
Two lipids were used for the vesicles: porcine brain phosphatidylserine (PS) (Avanti Polar 
Lipids, Alabaster, USA) and 1,2-dilauroyl-sn-glycero-3-phosphocholine (PC) (Avanti Polar 
Lipids, Alabaster, USA). Two types of vesicles were made using these lipids, vesicles 
containing 100% PC, or negatively-charged PC/PS (molar ratio 4:1) vesicles. To make these, 
the lipids were dissolved in chloroform within 1.5 mL polypropylene tubes.  The chloroform 
solution was spread evenly over the tube surface, and chloroform was evaporated off the tube 
surface using a stream of N2 gas. Residual chloroform was evaporated overnight in a vacuum 
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chamber. The lipids were then resuspended in deionized H2O (5 mg/mL for chemical stimuli 
assays, or 10 mg/mL for coating in microfluidic devices).  To obtain vesicles of a specific 
diameter (100 nm), samples were passed through membranes of successively smaller pore 
sizes (Northern Lipids, Burnaby, Canada) three times using a Lipex Thermobarrel Extruder 
(Northern Lipids, Burnaby, Canada). The vesicles extruded off the final 100 nm membrane 
were used for the experiments.  
Isolation, Culture, and FACS Analysis of PBMC. 
This study was approved by the research ethics boards of the University of British Columbia, 
and informed consent was obtained from all healthy volunteers before whole blood donation.  
Whole blood was collected into tubes containing sodium citrate (12 mM) before 1:1 dilution in 
buffer (PBS with 2% FBS). The mix was layered onto lymphocyte isolation density media 
(Ficoll-Paque PLUS, GE Healthcare Bio-Sciences AB, Uppsala, Sweden) and the PBMC were 
isolated according to previous literature with minor modifications4. The layered blood was 
centrifuged at 400 x g for 30 min at room temperature.  The PBMC layer was collected.  Two 
washes at 200 x g were performed in a buffered solution (PBS with 2% FBS) to remove the 
platelets from the supernatant. The PBMC pellet was then resuspended in culture medium 
(RPMI 1640; 50,000 U/L penicillin; 50 mg/L streptomycin; 25 mM HEPES; 20% FBS) at 1 x 
106 cells/mL. Cultures of 5 mL were either PBS-treated as an unstimulated control or 
stimulated with 1 µg/mL LPS. The cells were then incubated at 5% CO2 and 37˚C for 24 h. For 
each sample, 106 cells were spun down and resuspended in 1 µL of HEPES-citrate buffer. The 
cells were then added to the coagulation-controlled gel reaction mixture. To confirm expression 
of TF remaining cells were stained with Anti-Human CD142 PE (eBioscience, San Diego, CA) 
fluorescent antibody on ice for 30 min.  Propidium iodide was also added just before FACS 
analysis to stain for inviable cells.  The cells were analyzed using FACS Calibur (BD 
Biosciences, San Jose, CA).  Based on the light scatter, which indicates the cell size and 
granularity, PBMC were selected for analysis.  Single color controls were used to determine 
the background fluorescence level of each stain.  Based on this information, quadrants were 
drawn to indicate which cells were fluorescing above the threshold.  Target cells, which were 
both viable and expressed TF, were shown in the bottom right quadrant (Supplementary Fig. 
S8). 
 
Measuring plasmin-induced and bacteria-induced degradation of the BNC-material. 
Human plasmin (Haematologic Technologies Inc., Vermont, USA) was diluted in HEPES buffer 
and added to 3-μL BNC-material or fibrin clots (final plasmin concentration 333 μg/mL) pre-
formed in microchambers.  Microchambers were then sealed with immersion oil (type DF, code 
1261) (Cargille Laboratories, Inc., Cedar Grove, NJ) and the gels were monitored for lysis at 
37°C.  Degradation time was determined by measuring how long it took for the immobilized 
fluorescent beads to become liberated from the gel mesh and exhibit Brownian motion.  To 
measure degradation by bacteria, a similar procedure was used but plasmin was replaced with 
bacteria.  Glycerol stocks of bacterial strains (Bacillus thuringiensis Berliner ATCC #35646, 
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Bacillus subtilis subsp. spizizenii Nakamura et al. ATCC #6633, Bacillus cereus Frankland and 
Frankland ATCC #10987, Bacillus circulans Jordan ATCC #4513, Staphylococcus epidermidis 
(Winslow and Winslow) Evans ATCC #14990, Staphylococcus aureus subsp. aureus 
Rosenbach ATCC #25923) were streaked onto Difco™ LB agar, Lennox (BD Biosciences, San 
Jose, CA) plates.  The bacteria were cultured overnight at 37⁰C.  Colonies were picked and 
resuspended in the gel reaction buffer at 0.1 mg/mL.  The suspended bacteria (2.78 μL) were 
then added to 5 μL pre-formed BNC-material (final bacteria concentration 36 µg/mL) and 
degradation was measured.  
 
 
Supplementary Figure S1.  Two different polyamines can be used to form the BNC-
material. With either spermidine (which was used in the figures in the main text) or spermine, 
the BNC-material gelled faster or slower than inert controls in response to a known coagulation 
activator, thromboplastin, or an inhibitor, hirudin, respectively.  *p < 0.05.  Data indicate mean 
± SEM. n = 3-5. 
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Supplementary Figure S2.  The formation time of fibrin responds to diverse stimuli. 
Fibrin clots generated in recalcified normal plasma gelled faster or slower compared to the 
inert controls (blue) in response to known coagulation activators (green) and inhibitors (red), 
respectively.  Data indicate mean ± SEM. n = 3. 
 
 
Supplementary Figure S3.  Although modulators influence formation time, the physical 
properties of the final BNC-material are similar. The compressive elastic modulus of BNC-
material gels formed in the presence of a known coagulation activator, thromboplastin, and an 
inhibitor, hirudin, were not significantly different from inert controls (all  p > 0.05).  Data indicate 
mean ± SEM. n = 3-4. 
 
 
Supplementary Figure S4.  The molecular weights of PEG-mal and the resulting PEG-
peptide conjugate, measured by MALDI-TOF.  To facilitate this mass spec analysis, 20 kDa, 
4-armed PEG-mal was used rather than 40 kDa, 8-armed PEG-mal.  The 20 kDa, 4-armed 
PEG-mal was conjugated with four 1.7 kDa peptides.   
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Supplementary Figure S5. Gelation times of the BNC-material displays a threshold 
response to the FXIIIa concentration. Undesired precipitation occurred at 0.68 mg/ml of 
FXIIIa. 
 
Supplementary Figure S6. The physical properties of the BNC-material change when 
coagulation is activated. The shear elastic modulus of the activated BNC-material (purple 
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curve) was greater than the unstimulated BNC-material (black curve), normal plasma with fibrin 
(blue curve) and the BNC-material containing protease inhibitors (green curve) after 3 hr.  
 
 
 
Supplementary Figure S7.  Schematic of microchambers.  Adhesive silicone isolators 
formed an air-tight seal once sandwiched between two coverslips.  Each microchamber held a 
5 μL sample.   
 
 
 
Supplementary Figure S8.  PBMC were activated by LPS to express TF.  The bottom right 
quadrant of both graphs shows target cells that are viable and express tissue factor.  Viable 
TF-expressing cells were not consistently observed for the unstimulated control (0.06% of the 
population, shown on the plot on the left). A subpopulation of the PBMC expressed TF upon 
stimulation by LPS (6.98% of the population, shown on the plot on the right).  
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Supplementary Table S1. Enzyme activities of various plasma types.  Three different 
types of frozen human plasma were obtained (Affinity Biologicals, Ancaster, Canada).  Enzyme 
activity assays were performed by the manufacturer to determine activities. 
Plasma Type FII Activity 
FV 
Activity 
FVIII 
Activity 
Fibrinogen 
Concentration 
Normal plasma 1.12 U/ml 1.13 U/ml 1.22 U/ml 3.06 g/L 
Fibrinogen-deficient plasma (active 
cascade) 
1.02 
U/mL 
0.30 
U/mL 0.64 U/mL 0.06 g/L 
Fibrinogen-deficient and factors-
depleted plasma * 
0.79 
U/mL 
0.07 
U/mL 0.29 U/mL 0.001 g/L 
* FII, FV, and FVIII activities for this plasma are estimated based on the level of fibrinogen 
depletion relative to the other plasmas. 
Supplementary Table S2. Formation times of the BNC-material with various 
concentrations of modulators.  
Stimulus Manufacturer 
Final 
concentration 
Polymer 
gelation time 
[min] 
Human FXa Haematologic Technologies Inc., 
Vermont, USA 
100 μg/mL 
10 μg/mL 
33 
35 
Bovine 
Thrombin 
Sigma-Aldrich, St. Louis, USA 53 units/mL 
5.3 units/mL 
0.53 units/mL 
31 
31 
47 
Thromboplastin Pacific Hemostasis, Middletown, USA 6.6 mg/mL 
0.66 mg/mL 
0.066 mg/mL 
47 
29 
33 
Silica 
Particulates 
“Kontact,” Pacific Hemostasis, 
Middletown, USA 
13.3% (v/v) 
1.33% 
0.133% 
33 
29 
37 
APC Haematologic Technologies Inc., 
Vermont, USA 
50 μg/mL 
5 μg/mL 
152 
89 
DAPA Haematologic Technologies Inc., 
Vermont, USA 
100 μg/mL 
10 μg/mL 
100 
120 
Hirudin Sigma-Aldrich, St. Louis, USA 319 units/mL 
31.9 units/mL 
232 
194 
Rivaroxaban Sigma-Aldrich, St. Louis, USA 133 μM 
13.3 μM 
0.133 μM 
125 
204 
171 
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Fondaparinux “Xarelto,” Bayer HealthCare, Berlin, 
Germany 
133 μM 
13.3 μM 
0.133 μM 
171 
214 
191 
Silica (Fig. 2f) “SiMAG-Silanol,” Chemicell GmbH, 
Berlin, Germany 
66 μg/mL 
 
49 
 
Hydroxyl-coated 
silica 
“SiMAG-Hydroxyl,” Chemicell GmbH, 
Berlin, Germany 
66 μg/mL 
 
198 
Ellagic acid Sigma-Aldrich, St. Louis, USA 6.6 μM 118 
Rutin trihydrate Sigma-Aldrich, St. Louis, USA 6.6 μM 278 
Bolded values are the concentrations used in the main text.  
 
Supplementary Table S3. Degradation of the BNC-material is dependent on the 
concentration of plasmin.  
Final plasmin concentration Polymer degradation time [min] 
2000 μg/mL 
200 μg/mL 
20 μg/mL 
76 
124 
>900 
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